Vol. 20/No. 2 | OncologyLive

Blood Cancers Associated With Higher Treatment and Out-of-Pocket Costs

January 25, 2019

Patients with blood cancers face greater treatment costs than those with solid tumors. Furthermore, healthcare spending for these patients is already higher than average before diagnosis and does not return to prediagnosis levels even after successful treatment.

Evidence Grows for Earlier Immunotherapy in NSCLC

January 24, 2019

Clinical trial evidence is building for moving checkpoint blockade immunotherapy forward in the treatment timeline for non–small cell lung cancer, but improving patient selection for these therapies remains a key challenge.

NCI Moves to Expand Clinical Trial Eligibility Criteria

January 22, 2019

In en effort to ensure that study participants are more reflective of real-world populations, the National Cancer Institute has revised its clinical trial protocols to expand access for previously excluded patients.

More Progress Needed to Bring Oncology Practice Into the Digital Health Age

January 21, 2019

Much needs to be done to improve interoperability of medical data systems. However, standards and new systems are developing at a rapid pace, affording advantages and efficiencies where, previously, enormous impediments stood in the way.

Controversy Adds Caution to CRISPR Editing in United States

January 17, 2019

The development of cancer treatments and diagnostic tools using CRISPR/Cas9 and other gene-editing technology is a promising area of research in the United States, although the field is moving into human studies at a relatively slow pace.

MyDRUG Evaluates Targeted Agents in Multiple Myeloma

January 16, 2019

Investigators are taking a personalized approach to treating patients with multiple myeloma by introducing novel agents in combination with backbone chemotherapies, based on patients’ individual genetic profiles.